Yayi He1, Leslie Rozeboom2, Christopher J Rivard2, Kim Ellison2, Rafal Dziadziuszko3, Hui Yu2, Caicun Zhou4, Fred R Hirsch5. 1. Department of Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, Tongji University School of Medicine, Shanghai, 200433, People's Republic of China; Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, 80045, CO, USA. 2. Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, 80045, CO, USA. 3. Department of Oncology and Radiotherapy, Medical University of Gdansk, Poland. 4. Department of Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, Tongji University School of Medicine, Shanghai, 200433, People's Republic of China. Electronic address: Caicunzhoudr@163.com. 5. Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, 80045, CO, USA. Electronic address: Fred.Hirsch@ucdenver.edu.
Abstract
BACKGROUND: Immunotherapy is an exciting development in lung cancer research. In this study we described major histocompatibility complex (MHC) Class II protein expression in lung cancer cell lines and patient tissues. METHODS: We studied MHC Class II (DP, DQ, DR) (CR3/43, Abcam) protein expression in 55 non-small cell lung cancer (NSCLC) cell lines, 42 small cell lung cancer (SCLC) cell lines and 278 lung cancer patient tissues by immunohistochemistry (IHC). RESULTS: Seven (12.7%) NSCLC cell lines were positive for MHC Class II. No SCLC cell lines were found to be MHC Class II positive. We assessed 139 lung cancer samples available in the Hirsch Lab for MHC Class II. There was no positive MHC Class II staining on SCLC tumor cells. MHC Class II expression on TILs in SCLC was significantly lower than that on TILs in NSCLC (P＜0.001). MHC Class II was also assessed in an additional 139 NSCLC tumor tissues from Medical University of Gdansk, Poland. Patients with positive staining of MHC Class II on TILs had longer regression-free survival (RFS) and overall survival (OS) than those whose TILs were MHC Class II negative (2.980 years, 95% CI 1.628-4.332 vs. 1.050 years, 95% CI 0.556-1.554, P=0.028) (3.230 years, 95% CI 2.617-3.843 vs. 1.390 years, 95% CI 0.629-2.151, P=0.014). CONCLUSIONS: MHC Class II was expressed both in NSCLC cell lines and tissues. However, MHC Class II was not detected in SCLC cell lines or tissue tumor cells. MHC Class II expression was lower on SCLC TILs than on NSCLC TILs. Loss of expression of MHC Class II on SCLC tumor cells and reduced expression on SCLC TILs may be a means of escaping anti-cancer immunity. Higher MHC Class II expression on TILs was correlated with better prognosis in patients with NSCLC.
BACKGROUND: Immunotherapy is an exciting development in lung cancer research. In this study we described major histocompatibility complex (MHC) Class II protein expression in lung cancer cell lines and patient tissues. METHODS: We studied MHC Class II (DP, DQ, DR) (CR3/43, Abcam) protein expression in 55 non-small cell lung cancer (NSCLC) cell lines, 42 small cell lung cancer (SCLC) cell lines and 278 lung cancerpatient tissues by immunohistochemistry (IHC). RESULTS: Seven (12.7%) NSCLC cell lines were positive for MHC Class II. No SCLC cell lines were found to be MHC Class II positive. We assessed 139 lung cancer samples available in the Hirsch Lab for MHC Class II. There was no positive MHC Class II staining on SCLC tumor cells. MHC Class II expression on TILs in SCLC was significantly lower than that on TILs in NSCLC (P＜0.001). MHC Class II was also assessed in an additional 139 NSCLC tumor tissues from Medical University of Gdansk, Poland. Patients with positive staining of MHC Class II on TILs had longer regression-free survival (RFS) and overall survival (OS) than those whose TILs were MHC Class II negative (2.980 years, 95% CI 1.628-4.332 vs. 1.050 years, 95% CI 0.556-1.554, P=0.028) (3.230 years, 95% CI 2.617-3.843 vs. 1.390 years, 95% CI 0.629-2.151, P=0.014). CONCLUSIONS: MHC Class II was expressed both in NSCLC cell lines and tissues. However, MHC Class II was not detected in SCLC cell lines or tissue tumor cells. MHC Class II expression was lower on SCLC TILs than on NSCLC TILs. Loss of expression of MHC Class II on SCLC tumor cells and reduced expression on SCLC TILs may be a means of escaping anti-cancer immunity. Higher MHC Class II expression on TILs was correlated with better prognosis in patients with NSCLC.
Authors: Elizabeth K Duperret; Alfredo Perales-Puchalt; Regina Stoltz; Hiranjith G H; Nitin Mandloi; James Barlow; Amitabha Chaudhuri; Niranjan Y Sardesai; David B Weiner Journal: Cancer Immunol Res Date: 2019-01-24 Impact factor: 11.151
Authors: Amber M Johnson; Bonnie L Bullock; Alexander J Neuwelt; Joanna M Poczobutt; Rachael E Kaspar; Howard Y Li; Jeff W Kwak; Katharina Hopp; Mary C M Weiser-Evans; Lynn E Heasley; Erin L Schenk; Eric T Clambey; Raphael A Nemenoff Journal: J Immunol Date: 2020-03-16 Impact factor: 5.422
Authors: Daphne W Dumoulin; Anne-Marie C Dingemans; Joachim G J V Aerts; Jordi Remon; Dirk K M De Ruysscher; Lizza E L Hendriks Journal: Transl Lung Cancer Res Date: 2021-06
Authors: Ehsan Ghorani; James L Reading; Jake Y Henry; Marc Robert de Massy; Rachel Rosenthal; Virginia Turati; Kroopa Joshi; Andrew J S Furness; Assma Ben Aissa; Sunil Kumar Saini; Sofie Ramskov; Andrew Georgiou; Mariana Werner Sunderland; Yien Ning Sophia Wong; Maria Vila De Mucha; William Day; Felipe Galvez-Cancino; Pablo D Becker; Imran Uddin; Theres Oakes; Mazlina Ismail; Tahel Ronel; Annemarie Woolston; Mariam Jamal-Hanjani; Selvaraju Veeriah; Nicolai J Birkbak; Gareth A Wilson; Kevin Litchfield; Lucia Conde; José Afonso Guerra-Assunção; Kevin Blighe; Dhruva Biswas; Roberto Salgado; Tom Lund; Maise Al Bakir; David A Moore; Crispin T Hiley; Sherene Loi; Yuxin Sun; Yinyin Yuan; Khalid AbdulJabbar; Samra Turajilic; Javier Herrero; Tariq Enver; Sine R Hadrup; Allan Hackshaw; Karl S Peggs; Nicholas McGranahan; Benny Chain; Charles Swanton; Sergio A Quezada Journal: Nat Cancer Date: 2020-05-22